Cocrystal Pharma - Stock Price History | COCP

Historical daily share price chart and data for Cocrystal Pharma since 2021 adjusted for splits. The latest closing stock price for Cocrystal Pharma as of October 22, 2021 is 0.96.
  • The all-time high Cocrystal Pharma stock closing price was 6.25 on April 02, 2018.
  • The Cocrystal Pharma 52-week high stock price is 3.46, which is 260.4% above the current share price.
  • The Cocrystal Pharma 52-week low stock price is 0.76, which is 20.8% below the current share price.
  • The average Cocrystal Pharma stock price for the last 52 weeks is 1.30.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Cocrystal Pharma Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.1240 0.5400 2.3600 0.4800 1.3600 174.47%
2019 2.1165 3.7800 4.1400 0.3880 0.4955 -86.24%
2018 3.3270 4.7500 6.2457 1.6000 3.6000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.093B $0.002B
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76